| Identification | Back Directory | [Name]
Pyrrolo[1,2-a]quinoxalin-4(5H)-one,5-[3-[4-(4-chlorophenyl)-1-piperidinyl]propyl]- | [CAS]
1380392-05-1 | [Synonyms]
5-(3-(4-(4-chlorophenyl)piperidin-1-yl)propyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one
Pyrrolo[1,2-a]quinoxalin-4(5H)-one,5-[3-[4-(4-chlorophenyl)-1-piperidinyl]propyl]- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C25H26ClN3O | [MDL Number]
MFCD30489012 | [MOL File]
1380392-05-1.mol | [Molecular Weight]
419.95 |
| Chemical Properties | Back Directory | [Boiling point ]
603.8±55.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO:32.5(Max Conc. mg/mL);77.39(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);23.81(Max Conc. mM) | [form ]
Solid | [pka]
9.11±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells[1]. | [in vivo]
JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1]. | Animal Model: | SCID mice (~25g) with MDA-231 xenograft[1] | | Dosage: | 10 mg/kg | | Administration: | Aministered i.p.; twice a day for three weeks | | Result: | Caused a dramatic reduction of tumors in both skeleton and visceral organs. |
| [References]
[1] Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. DOI:10.1158/1541-7786.MCR-16-0013 |
|
|